-
Get to the point! You need to know these changes in the 2022 CSCO guidelines for the diagnosis and treatment of small cell lung cancer
Time of Update: 2023-02-02
smallknotIn general, the update of the 2022 edition of the CSCO guidelines for the diagnosis and treatment of small cell lung cancer mainly focuses on the treatment of extensive-stage SCLC, especially the recommended upgrade of chemotherapy + immunotherapy regimen for first-line therapy.
-
select the most appropriate IO-based first-line therapy for patients with advanced non-small cell lung cancer
Time of Update: 2023-01-05
(If you need the original text, you can add the editor WeChat yxj_oncology to get) Scan the QR code above to get more cutting-edge information1J Natl Cancer Inst: Certain clinicopathological and molecular predictors in combination with PD-L1 expression can help select the most appropriate IO-based first-line therapy for patients with advanced non-small cell lung cancer▎ Clinical problems: immunotherapy (IO) Many NSCLC patients do not benefit well.
-
For the treatment of advanced non-small cell lung cancer, AstraZeneca PD-1/TIGIT bispecific antibody initiates phase 2 clinical trial
Time of Update: 2023-01-05
▲If you have any business needs, please press and hold to scan the QR code above, or▎WuXi AppTec Content Team Editor Recently, AstraZeneca launched a Phase 2 clinical trial for its PD-1/ The TIGIT bispecific antibody AZD2936 was evaluated for its efficacy and safety in the treatment of patients with stage 3 unresectable or stage 4 non-small cell lung cancer (NCSLC).
-
LVGN7409 in combination with nivolumab injection for the treatment of non-small cell lung cancer
Time of Update: 2023-01-01
Lijin Biologics, an innovative biotechnology company focused on the development and commercialization of first-in-class and best-in-class oncology biologics, today announced the opening of an open-label, multicenter, randomized Phase II clinical trial to evaluate the efficacy and safety of LVGN7409 in combination with docetaxel or nivolumab in combination with Bristol-Myers Squibb in advanced/metastatic non-small cell lung cancer (NSCLC).
-
The latest results of the phase II study of QL1706 in the treatment of non-small cell lung cancer of Qilu Pharmaceutical were announced
Time of Update: 2023-01-01
By the end of the data, a total of 29 patients with EGFR wild-type advanced non-small cell lung cancer were enrolled and treated with QL1706 5 mg/kg combination chemotherapy (paclitaxel plus carboplatin or pemetrexed plus carboplatin) every 3 weeks (Q3W) and QL1706 5mg/kg Q3W maintenance therapy after 2 cycles until disease progression or other discontinuation events.
-
Henlius completed the first patient in the US to administer H drugs for first-line bridging studies in the treatment of extensive-stage small cell lung cancer
Time of Update: 2023-01-01
Based on the positive feedback from the FDA on the marketing application submitted for the treatment of extensive-stage small cell lung cancer (ES-SCLC) and the discussion results of the FDA Class C Advisory Meeting, the Company intends to recruit 200 US subjects to participate in this bridging clinical trial to evaluate the efficacy of H drug Hans-like ® in ES-SCLC patients in the United States.
-
AI facilitates drug development for non-small cell lung cancer, and XtalPi has reached a strategic cooperation with EDDC in Singapore
Time of Update: 2022-12-30
62em; font-family:"Arial"; color:black; margin:0in; } XtalPi has partnered with Singapore's National Drug Development Platform to develop more effective and precise treatment options for lung cancer patients worldwide SHENZHEN & SINGAPORE, Dec. 20, 2022 /PRNewswire/ -- XtalPi and Singapore's National Drug Development Platform, the Center for Experimental Drug Discovery (EDDC), have reached a strategic collaboration to drive drug discovery with artificial intelligence (AI), automated experiments, and expert experience for non-small cell lung cancer (NSCLC) targets selected by EDDC.
-
Small cell lung cancer, a competition of treatment options at home and abroad (2023.2 version)
Time of Update: 2022-11-25
NCCNClinical Practice Guidelines for Non-Small Cell Lung Cancer 2022. 5 (Chinese) (1), (2). NCCNSmall Cell Lung Cancer Clinical Practice Guidelines 2023. 2 (Chinese)CSCOGuidelines for the diagnosis a
-
The efficiency of small molecule organic solar cells can be increased by 50%
Time of Update: 2022-11-21
In some simple demonstrations, the research team led by Professor Allan tuned the thickness of the movable layer of a small molecule solar cell, embedding a zinc oxide optical interval between the movable layer and the metal electrode, so that more light can be captured and light absorption improved.
-
Embedded zinc oxide optical spacer Small molecule organic solar cells increase efficiency by 50%
Time of Update: 2022-11-17
According to the Physicists Organization Network recently reported, researchers at the University of California, Santa Barbara proved that just by tuning the thickness of the active layer and embedding an optical interval between the active layer and the electrode of a small molecule organic solar cell, its efficiency can be increased by 50%, from 6.
-
Express treatment of non-small cell lung cancer, potential "first-in-class" therapy demonstrates anti-cancer activity
Time of Update: 2022-11-15
▲If you have any business needs, please long press to scan the QR code above, or▎WuXi AppTec content team editorSurface Oncology today announced its potential "first-in-class" antibody SRF388 as a monotherapy for patients with non-small cell lung cancer (NSCLC).
-
Cell subjournal: Scientists study small intestinal flora for the first time through a human surgical stoma
Time of Update: 2022-11-15
On October 31, 2022, in a new study published in Cell Host & Microbe, a research team led by the University of Bern in Switzerland explored the ileal microbiome for the first time in patients with recovered colorectal cancer who had a surgical stoma.
-
J Clin Oncol: Efficacy of devarumab± tramimumab and chemotherapy in first-line treatment of metastatic non-small cell lung cancer
Time of Update: 2022-11-14
In summary, compared with chemotherapy alone, devarumab combined with chemotherapy significantly prolonged progression-free survival in patients with metastatic non-small cell lung cancer.
In summary, compared with chemotherapy alone, devarumab combined with chemotherapy significantly prolonged progression-free survival in patients with metastatic non-small cell lung cancer.
-
European Radiology: How can imaging be used to assess intratumoral immune status in non-small cell lung cancer?
Time of Update: 2022-11-04
In patients with NSCLC undergoing surgical resection (Resec1; Resec2; The internal cohort Resec3, n=419; the external cohort Resec4, n=96; and the TCIA cohort Resec5, n=55) explored the prognostic value of iEDI.
-
Next City Henlius Innovative Anti-PD-1 Monoclonal Antibody H Drug Hans Form? Approved for the treatment of squamous non-small cell lung cancer
Time of Update: 2022-11-04
/* Style Definitions */ span. prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a. prnews_a { color:blue; } li. prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p. prnews